Group 1 - The core message of the news is that China's National Medical Products Administration (NMPA) will enhance support for innovative drugs with new mechanisms and targets throughout the entire process from communication, clinical trials, registration, to review and approval, promoting "China's first launch" of innovative drugs [1][5] - By 2025, it is projected that 76 innovative drugs will be approved for market in China, with 80.85% of chemical drugs being domestic innovations and 91.3% of biological products being domestically developed [5][6] - The internationalization of China's pharmaceutical industry is advancing, with cumulative overseas licensing transactions for innovative drugs exceeding $130 billion, marking a shift from a "generic drug manufacturing powerhouse" to an "innovative drug exporting powerhouse" [6] Group 2 - The A-share market is seeing a strong performance in innovative drug concept stocks, with companies like Beibite-U and Hongbo Pharmaceutical experiencing significant price increases [2][3] - As of the end of 2025, the total market capitalization of 158 innovative drug concept stocks in the A-share market reached 3.42 trillion yuan, with several companies achieving over 100 billion yuan in market value [12][14] - The innovative drug sector is expected to remain a key investment theme in 2026, with a focus on clinical progress and data validation for pipelines that have already entered overseas markets [12][16]
国家药监局助力创新药“中国首发”，概念股持续火爆！
Ge Long Hui·2026-01-08 03:59